Digital Pathology Insights:
Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks

Available Now! Newly Released Report, with expanded focus, coverage and primary data!

New to Insight Pharma Reports is Digital Pathology Insights: Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks. This report delves into the rapidly evolving field of digital pathology, briefly reviewing the underlying scientific and technological concepts and providing an insightful perspective on various factors thought to be of significance to the development and future of this space.

Broken into several sections, the beginning of this report provides an overview of digital pathology including:

- Terminology and definitions
- Types of digital imaging systems (including whole slide scanners)
- Technical underpinnings
- Current and emerging applications

A brief overview of the digital pathology market will cover identified drivers and obstacles as well as current forecasts. The FDA and several standards organizations are profiled with regard to activities that may impact the furtherance of this field. Included in this section is an exclusive interview with Craig Revie, Chair of the International Color Consortium’s Medical Imaging Working Group and project coordinator for the development of a calibration system for digital microscopes.

Updated with all new interview with Thomas W. Bauer MD, PhD Medical Director for ePathology Medical Director, Cleveland Clinic Central Biorepository Departments of Pathology, Orthopedic Surgery and The Spine Center, Cleveland Clinic discussing Whole Slide Imaging Repository.

Companies featured in this report include:

- 3DHISTECH
- Applied Spectral Imaging
- Carl Zeiss Microscopy GmbH
- DigiPath Corp
- FFEI Ltd.
- Huron Technologies
- Nikon Instruments
- PerkinElmer
- Philips Digital Pathology Solutions

These companies have provided valuable insights as to the evolution of digital pathology within their businesses, the details of their current imaging systems, strategies, and techniques, as well as their individual perspectives on the establishment of standards in digital pathology, the challenges the field may face and the benefits that await as a digital environment becomes commonplace in pathology. Interviews with the expert company representatives are also included.

Finally, the report concludes with a unique look at the current climate of the digital pathology space based on a survey conducted by Insight Pharma Reports which polled a group of individuals identified as end users or developers of digital pathology technologies. An in depth analysis of these results compares the perspectives of both demographics on several important topics revealing areas of commonality and also divergence. Topics include areas most in need of improvement and the challenges and benefits associated with the use and development of digital pathology technologies.
Executive Summary

Digital Pathology Insights: Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks delves into the rapidly evolving field of digital pathology, briefly reviewing the underlying scientific and technological concepts and providing an insightful perspective on various factors thought to be of significance to the development and future of this space.

The opening chapters will provide an overview of digital pathology including: terminology and definitions for the purposes of this report, types of digital imaging systems (including whole slide scanners), and their technical underpinnings as well as current and emerging applications. A brief overview of the digital pathology market will cover identified drivers and obstacles as well as current forecasts. The U.S. Food and Drug Administration and several standards organizations will be profiled with regard to activities that may impact the furtherance of this field. Included in this section is an interview with Craig Revie, Chair of the International Color Consortium's Medical Imaging Working Group and project coordinator for the development of a calibration system for digital microscopes.

Participating companies, including 3DHISTECH, Applied Spectral Imaging, Carl Zeiss Microscopy GmbH, DigiPath Corp., FFEI Ltd., Huron Technologies, Nikon Instruments, PerkinElmer, and Philips Digital Pathology Solutions, have provided valuable insight as to the evolution of digital pathology within their businesses, the details of their current imaging systems, strategies, and techniques, as well as their individual perspectives on the establishment of standards in digital pathology, the challenges the field may face, and the benefits that await as a digital environment becomes commonplace in pathology. Interviews with the experts from the participating companies are also featured.

The report concludes with a unique look at the current climate of the digital pathology space based on a survey conducted by Insight Pharma Reports which polled a group of individuals identified as end users or developers of digital pathology technologies. Review of these results compares the perspectives of both demographics on several important topics revealing areas of commonality and also divergence. Topics include aspects of the technology that are in most need of improvement, and the challenges and benefits associated with the use and development of digital pathology technologies.
Report Contents

Executive Summary

PART 1: AN INTRODUCTION TO DIGITAL PATHOLOGY
CHAPTER 1
What is Digital Pathology?
Digital Imaging in Pathology
Whole Slide Imaging
A Brief Note on Telepathology

CHAPTER 2
Current and Emerging Applications
Current Applications
  Education
  Consultations and Second Opinions
  Frozen Section Interpretation
  Quality Assurance
  Image Analysis
Emerging Applications
  Multispectral Imaging
  WSI for Primary Diagnosis
  Computer Aided Diagnosis

CHAPTER 3
Market Outlook
What Will Facilitate the Adoption of Digital Pathology?
Barriers
Forecasts

CHAPTER 4
Regulation and Standards Development
  International Color Consortium (ICC)
  Digital Imaging and Communications in Medicine (DICOM)
  Standards Committee
  U.S. Food and Drug Administration (FDA)
  Clinical Laboratory Improvement Amendments (CLIA)
  College of American Pathologists (CAP)
  Interview with Craig Revie

PART II: DIGITAL IMAGING TECHNOLOGIES: MICROSCOPE IMAGING SYSTEMS
CHAPTER 5
Applied Spectral Imaging
  Company Background
  Technologies
  Collaboration
  Competitive Advantage
  Future Endeavors
  Digital Pathology Outlook: Standardization and Perspectives
  Interview with Limor Shiposh

  Company Background
  Technologies
  Collaboration
  Competitive Advantage
  Future Endeavors
  Digital Pathology Outlook: Standardization and Perspectives
CHAPTER 6
Nikon Instruments Inc.
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives
Interview with Stanley Schwartz

PART III: DIGITAL IMAGING TECHNOLOGIES: WHOLE SLIDE SCANNERS
CHAPTER 7
3DHISTECH Ltd.
Company Background
Technologies
P250 FLASH II Scanner
Pannoramic Confocal Scanner
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives
Interview with Dr. Viktor Varga

CHAPTER 8
Carl Zeiss Microscopy GmbH
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives
Interview with Dr. Thorsten Heupel

CHAPTER 9
DigiPath Corp.
Company Background
Technologies
Collaboration
Competitive Advantage
Digital Pathology Outlook: Standardization and Perspectives
Interview with Steve Barbee
CHAPTER 10
FFEI Ltd.
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives
Interview with George Hutchinson
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives

CHAPTER 12
Philips Digital Pathology Solutions
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives
Interview with Perry van Rijsingen
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives

CHAPTER 11
Huron Technologies
Company Background
Technologies
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives

CHAPTER 13
Whole Slide Scanners: A Comparison of Specifications

PART IV: INNOVATION SPOTLIGHT
CHAPTER 14
Innovation Spotlight: PerkinElmer
Company Background
Technologies
Vectra®
Lamina®
Collaboration
Competitive Advantage
Future Endeavors
Digital Pathology Outlook: Standardization and Perspectives

Interview with James Mansfield

Company Background
Technologies
Collaboration
Competitive Advantage
Digital Pathology Outlook: Standardization and Perspectives

PART V: A CASE STUDY - DIGITAL PATHOLOGY FOR PATIENT CARE: THE CLEVELAND CLINIC

CHAPTER 15

An Interview with Thomas W. Bauer MD, PhD

The Cleveland Clinic

PART VI: SURVEY RESULTS: END USER AND DEVELOPER PERSPECTIVES

CHAPTER 16

Survey Results
Technological Improvement
Challenges
Benefits
Additional Insights from Technology Developers
Additional Insights from End Users

References

About Cambridge Healthtech Institute

FIGURES

Figure 1.1. Continued Growth of Interest in Digital Pathology
Figure 2.1. Continued Growth of Interest in Multispectral Imaging
Figure 16.1. Survey Respondent Self-Identification
Figure 16.2. Comparison of End User and Developer Affiliations by Organization Type
Figure 16.3. Areas Having the Greatest Room for Improvement According to End Users
Figure 16.4. Aspects of Scanners Having the Greatest Room for Improvement According to End Users
Figure 16.5. Areas of Analysis Having the Greatest Room for Improvement According to End Users
Figure 16.6. Aspects of Scanners Having the Greatest Room for Improvement According to Developers
Figure 16.7. Aspects of Analysis Having the Greatest Room for Improvement According to Developers
Figure 16.8. Challenges Encountered in Technology Development
Figure 16.9. Challenges Facing End Users
Figure 16.10. Perceived Benefits Among End Users
Figure 16.11. End User Perspectives on Where Digital Pathology Will Have the Greatest Impact on Healthcare
Figure 16.12. Developer Perspectives on the Area That Will Benefit Most from Innovations in Digital Pathology Technologies
Figure 16.13. Types of Technologies Being Developed
Figure 16.14. Status of Current Technologies

Figure 16.15. Collaboration Among Technology Developers with Biotechnology and Pharmaceutical Companies

Figure 16.16. According to Developers, “An organization will be successful in digital pathology if it develops a technology that ________ than what is currently available.”

Figure 16.17. End User Areas of Research

Figure 16.18. End Users Indicate How Digital Pathology Applies to Their Work

TABLES

Table 5.1. Advantages of ASI’s GenASIs Platforms
Table 5.2. ASI GenASIs Imaging Platforms Overview
Table 6.1. DS-Fi2 Camera Overview
Table 6.2. DS-L3 Standalone Control Unit Overview
Table 6.3. Advantages of the Nikon Digital Sight System
Table 7.1. 3DHISTECH Pannoramic 250 FLASH II Benefits and Limitations
Table 7.2. 3DHISTECH Product Overview
Table 8.1. ZEISS Axio Scan.Z1 Benefits and Limitations
Table 8.2. ZEISS Axio Scan.Z1 Overview
Table 9.1. Advantages of the DigiPath PathScope
Table 9.2. DigiPath PathScope Overview
Table 10.1. FFEI Ltd. Dynamo Overview
Table 11.1. Huron Technologies TISSUEscope™ Benefits and Limitations
Table 11.2. Huron Technologies TISSUEscope™ Scanners Overview
Table 12.1. Philips Ultra Fast Scanner Benefits and Limitations
Table 12.2. Philips Ultra Fast Scanner Product Overview
Table 13.1. Product Comparison: Whole Slide Scanners
Table 14.1. Vectra® Automated Multispectral Imaging System Benefits and Limitations
Table 14.2. Lamina™ Multilabel Slide Scanner Benefits and Limitations
Table 14.3. Lamina™ Multilabel Slide Scanner Product Overview
About Insight Pharma Reports

CHI's Insight Pharma Reports are written by experts who collaborate with CHI to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.

Insight Pharma Reports are used by senior decision makers at life sciences companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts. Our clients include the top 50 pharmaceutical companies, top 100 biotechnology companies, and top 100 vendors of life science products and services. Typical purchasers are managers, directors, and VPs in business development, discovery research, clinical development, strategic planning, portfolio management, new product planning, and marketing.

Insight Pharma Reports offer:
- Current Information and analysis of R&D technologies, therapeutic markets, and critical business issues.
- Analysis of the probability of success for various applications of each technology.
- Expert insight based on interviews with key personnel in companies at the forefront of technological advances who share their views on their technology's current status, applications, future direction, and market environment.

Report Pricing

<table>
<thead>
<tr>
<th></th>
<th>Single User</th>
<th>Single Site</th>
<th>Multi Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$2,495</td>
<td>$3,995</td>
<td>$9,950</td>
</tr>
</tbody>
</table>

To Order

- InsightPharmaReports.com
- Phone: 781.972.5402
- Email: arandall@healthtech.com
- Mail: Cambridge Healthtech Institute
  Adriana Randall
  250 First Avenue, Suite 300
  Needham, MA 02494

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.

Contact:
Dan Miller
Marketing Manager
781-972-5492